These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 11418381)

  • 41. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease.
    Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Masmas TN; Dickmeiss E; Heilmann C; Vindeløv LL
    Biol Blood Marrow Transplant; 2004 May; 10(5):337-46. PubMed ID: 15111933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood.
    Klumpp TR
    N Engl J Med; 2001 May; 344(21):1641; author reply 1641-2. PubMed ID: 11374366
    [No Abstract]   [Full Text] [Related]  

  • 44. Peripheral blood progenitor cell or bone marrow transplantation: controversy remains.
    Koca E; Champlin RE
    Curr Opin Oncol; 2008 Mar; 20(2):220-6. PubMed ID: 18300773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
    Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
    Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients.
    Tabata M; Satake A; Okura N; Yamazaki Y; Toda A; Nishioka K; Tanaka H; Chin M; Itsukuma T; Yamaguchi M; Misawa M; Kai S; Hara H
    Ann Hematol; 2002 Oct; 81(10):582-7. PubMed ID: 12424540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dendritic cell recovery after autologous stem cell transplantation.
    Damiani D; Stocchi R; Masolini P; Michelutti A; Sperotto A; Geromin A; Skert C; Cerno M; Michieli M; Baccarani M; Fanin R
    Bone Marrow Transplant; 2002 Sep; 30(5):261-6. PubMed ID: 12209346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allogeneic blood stem cell transplantation.
    Ehninger G; Bornhäuser M
    Eur J Cancer; 2009 Sep; 45 Suppl 1():412-3. PubMed ID: 19775651
    [No Abstract]   [Full Text] [Related]  

  • 50. [Bone marrow transplantation].
    Sosa-Sánchez R; Deeg HJ; Sobrevilla-Calvo P
    Rev Invest Clin; 1997 May; 49 Suppl 1():75-82. PubMed ID: 9380993
    [No Abstract]   [Full Text] [Related]  

  • 51. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overview of bone marrow and stem cell transplantation.
    Johns A
    J Intraven Nurs; 1998; 21(6):356-60. PubMed ID: 10392101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives.
    Ringdén O; Le Blanc K
    APMIS; 2005; 113(11-12):813-30. PubMed ID: 16480452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
    Mehta J; Gordon LI; Tallman MS; Winter JN; Evens AM; Frankfurt O; Williams SF; Grinblatt D; Kaminer L; Meagher R; Singhal S
    Bone Marrow Transplant; 2006 Jul; 38(2):95-100. PubMed ID: 16751789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.
    Stelljes M; van Biezen A; Slavin S; Olavarria E; Clark RE; Nagler A; Koza V; Kienast J; Niederwieser D; de Witte T; Ruutu T;
    Bone Marrow Transplant; 2008 Dec; 42(11):739-42. PubMed ID: 18724394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies.
    Yamasaki S; Ohno Y; Taniguchi S; Yoshida T; Hayashi S; Ogawa H; Shimazaki C; Takahashi S; Kasai M; Wake A; Nishimura M; Tokunaga K; Gondo H; Takaue Y; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Feb; 33(3):279-89. PubMed ID: 14647250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease.
    Abrahamsen IW; Sømme S; Heldal D; Egeland T; Kvale D; Tjønnfjord GE
    Haematologica; 2005 Jan; 90(1):86-93. PubMed ID: 15642674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haploidentical hematopoietic stem cell transplantation in child hematologic malignancies with G-CSF-mobilized marrow grafts without T-cell depletion: a single-center report of 45 cases.
    Wang HX; Yan HM; Duan LN; Wang ZD; Zhu L; Xue M; Liu J; Hu LD; Guo ZK
    Pediatr Hematol Oncol; 2009; 26(3):119-28. PubMed ID: 19382033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.